Cargando…
HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway
BACKGROUND: Pediatric high-grade gliomas (pHGGs) are an aggressive CNS tumor which are often characterized by mutations in H3F3A, the gene that encodes Histone H3.3 (H3.3). A substitution of the Glycine at position 34 of H3.3 with either Arginine or Valine (H3.3G34R/V), was recently described in a l...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164885/ http://dx.doi.org/10.1093/neuonc/noac079.217 |
_version_ | 1784720251489878016 |
---|---|
author | Abdallah, Aalaa Cardona, Herminio Gadd, Samantha Brat, Daniel Picketts, David Becher, Oren Li, Xiao-Nan |
author_facet | Abdallah, Aalaa Cardona, Herminio Gadd, Samantha Brat, Daniel Picketts, David Becher, Oren Li, Xiao-Nan |
author_sort | Abdallah, Aalaa |
collection | PubMed |
description | BACKGROUND: Pediatric high-grade gliomas (pHGGs) are an aggressive CNS tumor which are often characterized by mutations in H3F3A, the gene that encodes Histone H3.3 (H3.3). A substitution of the Glycine at position 34 of H3.3 with either Arginine or Valine (H3.3G34R/V), was recently described in a large cohort of pHGG samples and has been characterized as occurring in anywhere between 5-20% of pHGGs. Attempts to study the mechanisms of H3.3G34R have proven difficult due to the developmental nature of the disease and the requirement of co-occurring mutations for model development. METHODS: We utilized the RCAS system to develop a genetically engineered mouse model (GEMM) that incorporates PDGF-A activation, TP53 loss and the H3.3G34R mutation both in the context of ATRX loss and ATRX presence in nestin expressing progenitors. RESULTS: We show that in H3.3G34R expressing mice, ATRX loss significantly increased tumor latency from 90 days to 143 days (p < 0.01, Log rank test) and decreased tumor incidence from 81% to 57% (p < 0.01, Fisher’s exact test). By contrast, H3.3G34R did not significantly impact tumor latency in either our ATRX loss (163 days to 143 days, p = 0.178, Log-rank test) or our ATRX expressing (95 days to 90 days, p = 0.415, Log-rank test) models. Transcriptomic analysis revealed that ATRX loss in the context of H3.3G34R upregulates the PRC2 associated genes Hoxa2, Hoxa3, Hoxa5, and Hoxa7 (p < 0.05, unpaired t-test). GSEA analysis and RT-qPCR data suggest that ATRX loss works synergistically with H3.3G34R to promote NOTCH pathway activation through upregulation of the NOTCH ligand Dll3 (p < 0.01, unpaired t-test). CONCLUSIONS: Our study proposes a model in which ATRX loss is the major contributor to transcriptomic changes in the majority of H3.3G34R pHGGs. Broadly, our work highlights the importance of studying mechanisms of co-occurring genetic events separately and in combination. |
format | Online Article Text |
id | pubmed-9164885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91648852022-06-05 HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway Abdallah, Aalaa Cardona, Herminio Gadd, Samantha Brat, Daniel Picketts, David Becher, Oren Li, Xiao-Nan Neuro Oncol High Grade Glioma BACKGROUND: Pediatric high-grade gliomas (pHGGs) are an aggressive CNS tumor which are often characterized by mutations in H3F3A, the gene that encodes Histone H3.3 (H3.3). A substitution of the Glycine at position 34 of H3.3 with either Arginine or Valine (H3.3G34R/V), was recently described in a large cohort of pHGG samples and has been characterized as occurring in anywhere between 5-20% of pHGGs. Attempts to study the mechanisms of H3.3G34R have proven difficult due to the developmental nature of the disease and the requirement of co-occurring mutations for model development. METHODS: We utilized the RCAS system to develop a genetically engineered mouse model (GEMM) that incorporates PDGF-A activation, TP53 loss and the H3.3G34R mutation both in the context of ATRX loss and ATRX presence in nestin expressing progenitors. RESULTS: We show that in H3.3G34R expressing mice, ATRX loss significantly increased tumor latency from 90 days to 143 days (p < 0.01, Log rank test) and decreased tumor incidence from 81% to 57% (p < 0.01, Fisher’s exact test). By contrast, H3.3G34R did not significantly impact tumor latency in either our ATRX loss (163 days to 143 days, p = 0.178, Log-rank test) or our ATRX expressing (95 days to 90 days, p = 0.415, Log-rank test) models. Transcriptomic analysis revealed that ATRX loss in the context of H3.3G34R upregulates the PRC2 associated genes Hoxa2, Hoxa3, Hoxa5, and Hoxa7 (p < 0.05, unpaired t-test). GSEA analysis and RT-qPCR data suggest that ATRX loss works synergistically with H3.3G34R to promote NOTCH pathway activation through upregulation of the NOTCH ligand Dll3 (p < 0.01, unpaired t-test). CONCLUSIONS: Our study proposes a model in which ATRX loss is the major contributor to transcriptomic changes in the majority of H3.3G34R pHGGs. Broadly, our work highlights the importance of studying mechanisms of co-occurring genetic events separately and in combination. Oxford University Press 2022-06-03 /pmc/articles/PMC9164885/ http://dx.doi.org/10.1093/neuonc/noac079.217 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | High Grade Glioma Abdallah, Aalaa Cardona, Herminio Gadd, Samantha Brat, Daniel Picketts, David Becher, Oren Li, Xiao-Nan HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway |
title | HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway |
title_full | HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway |
title_fullStr | HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway |
title_full_unstemmed | HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway |
title_short | HGG-01. A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes and promotion of the NOTCH pathway |
title_sort | hgg-01. a novel genetically engineered h3.3g34r model reveals cooperation with atrx loss in upregulation of prc2 target genes and promotion of the notch pathway |
topic | High Grade Glioma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164885/ http://dx.doi.org/10.1093/neuonc/noac079.217 |
work_keys_str_mv | AT abdallahaalaa hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway AT cardonaherminio hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway AT gaddsamantha hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway AT bratdaniel hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway AT pickettsdavid hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway AT becheroren hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway AT lixiaonan hgg01anovelgeneticallyengineeredh33g34rmodelrevealscooperationwithatrxlossinupregulationofprc2targetgenesandpromotionofthenotchpathway |